Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treatment for complicated urinary tract infections, the company and its partner GSK have pushed Utebzi across the finish line. More: 4 years after snub,
read moreWith good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib in first-line metastatic pancreatic cancer, Verastem Oncology will now channel its primary R&D efforts toward other pipeline darlings. More: Despite 'decent' data, Verastem rethinks options for approved
read moreEighteen months after Novo Nordisk purchased a plant in the Czech Republic from Novavax, the Danish drugmaker said it is set to kick off the manufacturing of ingredients for next-generation diabetes and obesity drugs at the facility. The company also
read moreGSK has launched the first direct-to-consumer TV spot for Exdensur, stepping up promotion of an asthma drug that the company is tipping to generate blockbuster sales. More: GSK runs first DTC ad for would-be asthma blockbuster Exdensur Source: fierce
read moreTwo different hacking rings acquired sensitive information from Novo and allegedly attempted to extort the company out of millions of dollars. More: Novo security breach claimed by hacking groups seeking multi-million-dollar ransoms: reports Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals